<DOC>
	<DOCNO>NCT00068406</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy cisplatin use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Giving chemotherapy radiation therapy surgery may shrink tumor remove surgery . PURPOSE : This phase II trial study well give radiation therapy together cisplatin follow surgery work treat patient locally advanced cancer vulva .</brief_summary>
	<brief_title>Chemotherapy , Radiation Therapy , Surgery Treating Patients With Locally Advanced Cancer Vulva</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy radiotherapy cisplatin , term achieve complete clinical pathological response , patient locally advance squamous cell carcinoma vulva amenable standard radical vulvectomy . - Determine toxicity regimen follow surgery patient . OUTLINE : This multicenter study . Patients undergo radiotherapy daily day 1-5 receive concurrent cisplatin IV 30 minute day 1 . Treatment repeat weekly approximately 6.5 week ( total 32 fraction radiotherapy ) absence unacceptable toxicity . Six eight week completion chemoradiotherapy , patient complete clinical response may undergo incisional biopsy primary tumor bilateral inguinal/femoral node ( groin node initially unresectable ) . Patients microscopic gross resectable residual disease may undergo radical resection residual tumor . Patients unresectable disease completion chemoradiotherapy receive additional radiotherapy 1-2 course concurrent cisplatin . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 25-58 patient accrue study within 1.8-2.3 year .</detailed_description>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis locally advance squamous cell carcinoma vulva T3 T4 ( N03 , M0 ) Not amenable surgical resection standard radical vulvectomy Previously untreated disease No recurrent disease No vulvar melanoma sarcoma PATIENT CHARACTERISTICS : Age Any age Performance status GOG 03 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 time normal Alkaline phosphatase great 3 time normal SGOT great 3 time normal Renal Creatinine great 2.0 mg/dL Gastrointestinal No gastrointestinal bleeding No severe gastrointestinal symptom Other Capable tolerate radical course chemoradiotherapy No septicemia No severe infection No invasive malignancy within past 5 year except nonmelanoma skin cancer No circumstance would preclude study completion followup PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior cytotoxic chemotherapy Endocrine therapy Not specify Radiotherapy No prior pelvic radiotherapy No concurrent boost brachytherapy Surgery Not specify Other No prior anticancer therapy would contraindicate study therapy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>squamous cell carcinoma vulva</keyword>
	<keyword>stage III vulvar cancer</keyword>
	<keyword>stage IVB vulvar cancer</keyword>
</DOC>